Track market-moving stories before they get noisy

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Key Takeaways Harmony Biosciences reported about $261M in preliminary Q2 2026 Wakix net product revenues, up 30% Y/Y.HRMY reaffirmed 2026 net product revenue guidance of $1.0-$1.04B after a strong first half.HRMY advances pitolisant programs and named an interim finance chief after its CFO stepped down. Harmony Biosciences (HRMY - Free Report) announced preliminary second-quarter 2026 results.

The company registered a record $261 million in net product revenues from its lead drug, Wakix (pitolisant).

Wakix received FDA approval in August 2019 to treat excessive daytime sleepiness (EDS) in adults with narcolepsy and was launched in the United States in November 2019. In October 2020, the FDA expanded its approval to include the treatment of cataplexy in adults with narcolepsy.

Revenues increased 30% year over year and 21% sequentially from the first quarter, reflecting continued strong demand and solid commercial execution.

Encouraged by its first-half performance, the company reiterated its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, signaling confidence in sustained growth for the remainder of the year.

Harmony is scheduled to report its complete second-quarter 2026 financial results and provide a business update on Aug. 4, 2026.

Shares of HRMY have lost 10.4% year to date against the industry’s 1.7% gain.

Image Source: Zacks Investment Research

HRMY’s CFO Steps DownHarmony announced that chief financial officer (CFO) Glenn Reicin has stepped down, effective July 16, 2026, to pursue other opportunities.

The company appointed Stephen Mollichella, currently senior vice president and controller, as interim principal financial officer while it conducts a search for a permanent CFO.

HRMY’s Efforts to Strengthen BusinessHarmony is pursuing label expansion opportunities for pitolisant beyond narcolepsy, targeting rare neurological disorders such as Prader-Willi syndrome (PWS) and myotonic dystrophy type 1 (DM1).

The company is conducting the phase III TEMPO study in PWS, supported by FDA alignment, which has the potential to serve as the registrational trial and support the company’s efforts to seek pediatric exclusivity for pitolisant.

The FDA granted Orphan Drug designation to pitolisant for the treatment of PWS in 2024.

In DM1, phase II data demonstrated meaningful improvements in EDS and fatigue, supporting further development.

Wakix has also expanded into the pediatric narcolepsy market, with FDA approval for EDS in 2024.

In February 2026, the FDA also approved Wakix for the treatment of cataplexy in patients six years and older with narcolepsy, providing additional long-term growth opportunities for the franchise.

Meanwhile, Harmony is advancing two next-generation formulations of pitolisant to strengthen and extend this franchise.

The company is on track to submit a new drug application for pitolisant GR (gastro-resistant) shortly. A decision from the FDA is expected in the first quarter of 2027. The formulation features an enteric coating designed to reduce gastrointestinal side effects, allowing patients to start treatment at a therapeutic dose without titration. Harmony has filed utility patents that could extend the pitolisant franchise into the 2040s.

HRMY is also developing pitolisant HD (high dose) to further expand the franchise. Phase III studies are underway in narcolepsy (ONSTRIDE 1) and idiopathic hypersomnia (ONSTRIDE 2), with top-line data expected in 2027. The enhanced formulation is designed to improve efficacy through optimized pharmacokinetics, an enteric coating and a higher dose, while supporting differentiated labeling for fatigue in narcolepsy and sleep inertia in idiopathic hypersomnia. Utility patents for Pitolisant HD have also been filed, supporting franchise protection into the 2040s.

HRMY’s Zacks Rank and Other Stocks to Consider HRMY currently carries a Zacks Rank #1 (Strong Buy). A couple of other top-ranked stocks from the sector are Liquidia Corporation (LQDA - Free Report) and Novavax (NVAX - Free Report) , each sporting a Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share (EPS) have increased from $2.97 to $3.02. Over the same period, EPS estimates for 2027 have also increased from $4.81 to $4.92. LQDA shares have skyrocketed more than 118.3% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Novavax’s 2026 loss per share have narrowed from 20 cents to 19 cents. Over the same period, loss per share estimates for 2027 have narrowed from 31 cents to 25 cents. NVAX shares have gained nearly 22.7% year to date.

Novavax’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 305.24%.

Harmony Biosciences Holdings, Inc. (HRMY - Free Report) closed the last trading session at $34.81, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $44.33 indicates a 27.4% upside potential.

The average comprises 12 short-term price targets ranging from a low of $28.00 to a high of $85.00, with a standard deviation of $15.28. While the lowest estimate indicates a decline of 19.6% from the current price level, the most optimistic estimate points to a 144.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

However, an impressive consensus price target is not the only factor that indicates a potential upside in HRMY. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Here's Why There Could be Plenty of Upside Left in HRMYThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The Zacks Consensus Estimate for the current year has increased 1.7% over the past month, as one estimate has gone higher compared to no negative revision.

Moreover, HRMY currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much HRMY could gain, the direction of price movement it implies does appear to be a good guide.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One company value investors might notice is Harmony Biosciences (HRMY - Free Report) . HRMY is currently sporting a Zacks Rank #1 (Strong Buy) and an A for Value.

Investors should also recognize that HRMY has a P/B ratio of 2.42. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 3.54. Over the past year, HRMY's P/B has been as high as 4.20 and as low as 2.23, with a median of 2.87.

Finally, our model also underscores that HRMY has a P/CF ratio of 9.34. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. HRMY's current P/CF looks attractive when compared to its industry's average P/CF of 9.69. Within the past 12 months, HRMY's P/CF has been as high as 16.61 and as low as 9.07, with a median of 11.73.

These are only a few of the key metrics included in Harmony Biosciences's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, HRMY looks like an impressive value stock at the moment.

Key Takeaways Harmony Biosciences is expanding pitolisant into idiopathic hypersomnia and rare disorders.HRMY is advancing Pitolisant GR and HD to improve dosing, tolerability and differentiation.HRMY is developing BP-205 and EPX-100 to broaden its neuroscience pipeline footprint. Harmony Biosciences Holdings, Inc. (HRMY - Free Report) is no longer only a Wakix revenue story. The company is using its sleep-wake franchise to fund a broader neuroscience strategy.

The central question is whether those emerging growth trends can turn pipeline investment into a more diversified business before competition and exclusivity risks pressure the core product.

Harmony Pushes Beyond One IndicationHarmony is working to extend pitolisant beyond its established narcolepsy base. Its late-stage clinical work includes idiopathic hypersomnia, Prader-Willi syndrome and myotonic dystrophy type 1.

That approach reflects a broader attempt to extract more value from an established mechanism across adjacent neurological settings. Rather than relying only on new patient starts in narcolepsy, HRMY is trying to build a wider clinical footprint around the same scientific foundation.

Why HRMY Is Chasing Better FormulationsPitolisant Gastro-Resistant and Pitolisant High-Dose are central to that lifecycle strategy. The gastro-resistant version is intended to allow patients to start at a therapeutic dose without titration, while potentially improving tolerability for patients prone to gastrointestinal symptoms.

The high-dose version targets a more differentiated label. Ongoing Phase III programs in narcolepsy and idiopathic hypersomnia are aimed at fatigue in narcolepsy and sleep inertia in idiopathic hypersomnia, with top-line data expected in 2027 and a target action date in 2028. For HRMY, formulation work is not just incremental. It is a way to defend the franchise and sharpen commercial positioning.

How Harmony Is Entering Orexin and Rare EpilepsyHarmony’s BP1.15205 program moves the company into orexin-2 receptor agonism, an emerging area in sleep-wake therapeutics. The candidate is being developed for narcolepsy and other potential indications, and Harmony has described BP-205 as a highly potent, selective orexin-2 receptor agonist with potential once-daily dosing.

The company is also moving deeper into rare epilepsy through EPX-100, or clemizole hydrochloride. EPX-100 is enrolling in two global Phase III registrational trials in Lennox-Gastaut syndrome and Dravet syndrome. Jazz Pharmaceuticals plc (JAZZ - Free Report) , which has exposure to rare sleep disorders and rare epilepsies, offers a useful comparison for how sleep and epilepsy franchises can sit within one neuroscience business.

Alkermes plc (ALKS - Free Report) , another neuroscience-focused peer, also highlights investor interest in central nervous system portfolios beyond single-product stories.

What Competition Means for HRMY’s FutureMore treatment development in narcolepsy and related disorders can help validate demand. A more active category may increase physician awareness, expand payer familiarity and reinforce the need for differentiated therapies.

The same trend also raises pressure. Multiple orexin-2 receptor agonists are moving toward approval or late-stage development, while Harmony’s BP-205 remains early. More choices could narrow the window for differentiation, increase payer scrutiny and make execution around access, positioning and persistence more important.

How Harmony’s Ratings Reflect These TrendsThe bottom line is that Harmony has credible growth trends, but the stock still needs proof that they can translate into broader revenue durability. Wakix remains the commercial engine, while pitolisant lifecycle programs, orexin science and rare epilepsy assets represent the next phase of the story.

HRMY carries a Zacks Rank #3 (Hold), which points to a more balanced short-term setup rather than a clear momentum call. Its Value Score of A and VGM Score of A suggest the stock screens well on valuation and combined style characteristics, while its Growth Score of B supports the view that fundamental expansion remains part of the case.

The Momentum Score of D tempers that message. Investors may need patience as the market waits for clearer evidence from Pitolisant GR, Pitolisant HD, BP-205 and EPX-100. The signals line up with a company investing into promising trends, but not yet with a stock that has fully earned a breakout narrative.

Key Takeaways Harmony Biosciences trades at 10.38X forward earnings, below industry and market averages.HRMY reiterated 2026 Wakix guidance despite missing earnings and revenue estimates in Q1.HRMY is advancing Pitolisant GR and HD programs while expanding rare epilepsy studies. Harmony Biosciences Holdings, Inc. (HRMY - Free Report) sits at an interesting point for investors. The stock looks inexpensive by several valuation measures, but the company depends heavily on Wakix for revenues.

That creates a balanced buy debate. HRMY has a profitable commercial franchise and a funded pipeline, yet recent misses keep the setup from looking one-sided.

Why HRMY Looks Cheap on PaperHRMY’s valuation profile is the clearest part of the bull case. The stock trades at 10.38X forward 12-month earnings, below 44.24X for the Zacks sub-industry, 21.22X for the Zacks sector and 20.9X for the S&P 500 index.

Other measures also look restrained. HRMY has a current-year price-to-earnings ratio of 11.08, a PEG ratio of 0.70, a price-to-sales ratio of 2.28 and a price-to-book ratio of 2.25. The discount reflects a business concentrated around one commercial product and exposed to future competition and generic risk.

Where Harmony Still Shows Operating StrengthHarmony still has operating support behind the valuation argument. In 2025, the company reported net product revenues of $868.5 million, up from $714.7 million in 2024. It also reiterated 2026 Wakix net revenue guidance of $1.0 billion to $1.04 billion.

The balance sheet adds flexibility. Harmony ended the first quarter of 2026 with $870.5 million in cash, cash equivalents and investments. Consensus estimates also imply growth, with sales projected at $1.009 billion in 2026 and $1.129 billion in 2027, while earnings are projected at $3.20 per share in 2026 and $3.64 per share in 2027.

Alkermes plc (ALKS - Free Report) gives investors another neuroscience peer to watch. Jazz Pharmaceuticals plc (JAZZ - Free Report) , with its sleep medicine presence, remains a relevant specialty pharma comparison.

Why Recent Results Raise CautionThe latest quarter introduced caution. Harmony reported earnings of 55 cents per share, below the Zacks Consensus Estimate of 76 cents and down from 78 cents in the year-ago period.

Net product revenues were $215.4 million, up 17% year over year, but they missed the Zacks Consensus Estimate of $222 million. The company exited the quarter with roughly 8,600 patients on therapy.

Management cited seasonal market access headwinds, including plan changes, prior authorizations and premium resets, that delayed starts. This pattern occurs in the first quarter, but it was more pronounced this year.

Spending also moved higher. Research and development expenses more than doubled to $69.3 million, reflecting pipeline expansion and licensing transactions. That spending could pay off, but it raises the execution bar.

What Could Re-Rate HRMY StockA stronger stock case starts with Wakix. Smooth progress toward the 2026 revenue target would help show that access friction is manageable and that the narcolepsy opportunity remains underpenetrated.

Pipeline execution is the second lever. Pitolisant GR is on track for an NDA submission in the second quarter, with a target action date in the first quarter of 2027. The formulation is designed to start patients at a therapeutic dose and potentially improve tolerability.

Pitolisant HD is another key program, with phase III studies in narcolepsy and idiopathic hypersomnia. Top-line data are anticipated in 2027, and a target action date is expected in 2028.

Investors will also watch whether pipeline spending can create future revenue streams. EPX-100 is enrolling in two phase III rare epilepsy studies, while amorphous pitolisant could open broader central nervous system indications.

How Harmony’s Ratings Shape the Buy DebateThe bottom line is that HRMY looks more like a valuation-driven watchlist candidate than a clean momentum buy. Low multiples and revenue growth are appealing, but recent misses and product concentration keep the risk-reward balanced.

The Neutral long-term view argues against an aggressive call. The stock currently carries a Zacks Rank #3 (Hold), which suggests a measured near-term setup rather than a clear signal for immediate outperformance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores are more constructive on valuation and fundamentals. HRMY has a VGM Score of A, a Value Score of A and a Growth Score of B, supporting the case that the shares screen well for value and business expansion.

The Momentum Score of D is the offset. It suggests investors may need patience for the valuation case to work while the market waits for steadier execution and clearer pipeline progress.

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical compan.

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and pri.

Harmony Biosciences (NASDAQ:HRMY) executives outlined 2026 priorities at Needham & Company’s Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications.

WAKIX outlook and commercial execution President and CEO Jeffrey Dayno said Harmony is “on track to achieve over $1 billion in net revenue for WAKIX in its sixth year on the market,” describing the product as the company’s foundation for near- and long-term growth.

Chief Commercial Officer Adam Zaeske pointed to accelerating patient growth exiting 2025. While the company “typically see[s] patient additions of 100-400 patients a quarter,” Zaeske said the last three quarters saw “400-500 patient adds,” which he characterized as “really, really strong growth and momentum carrying us into 2026.” He attributed the performance to WAKIX’s differentiation as “the only non-scheduled treatment option available for patients,” along with broad access and ongoing refinements to sales execution, payer coverage, and patient support processes intended to speed time to dispense.

Looking ahead, Zaeske said Harmony expanded its commercial organization in the first quarter, increasing field sales, remote sales, and field reimbursement teams “on average of about 20%,” with hires in place and trained.

ANDA litigation and loss-of-exclusivity planning Fadia asked about an outstanding abbreviated new drug application (ANDA) filer. Dayno said Harmony has “settled with six of the seven ANDA filers” with loss of exclusivity (LOE) “to September of 2029,” and he added that pediatric exclusivity—“for which we’re on track to achieve”—would extend that to “March of 2030.”

On the ongoing trial process, Dayno said post-trial briefs were submitted the prior Thursday and the company cannot “predict the timing or the outcome.” He said Harmony remains focused both on completing settlement efforts and on advancing next-generation pitolisant programs.

Pitolisant franchise: GR and high-dose programs Dayno highlighted multiple pitolisant lifecycle initiatives. He said pitolisant GR (gastroresistant) is “on track for NDA submission this quarter,” with a target PDUFA date in “the first quarter of next year of 2027.”

Zaeske said the GR formulation is intended to improve the patient experience, noting that “80% of patients with narcolepsy have the potential for GI symptoms related to the disease.” He said the GR coating “adds to” WAKIX’s tolerability foundation and also enables patients to “start at a therapeutic dose” with “no titration required.” Zaeske added that Harmony’s distribution model allows it to recontact prior WAKIX patients who consented at initiation, potentially informing patients who discontinued for various reasons that a GR formulation is available. He said Harmony has “historically…thought about the GR as between $3 million and $500 million opportunity.”

For pitolisant high dose (HD), Zaeske described the strategy as “a totally new branded launch and a highly differentiated product,” combining the GR benefits with “up to 2x the approved dose of WAKIX” and pursuing “unique indications in narcolepsy and IH.” He said the company is running two phase III registrational trials—one in narcolepsy and one in idiopathic hypersomnia (IH)—with “target PDUFA dates both in 2028,” and said Harmony has discussed HD as “a billion-plus opportunity.”

Dayno added that HD is “a unique formulation” with “a different PK profile,” stating that “milligram for milligram, greater exposure” has been demonstrated, with safety margins “well beyond going two times the highest labeled dose.” He also said the GR and HD programs are designed to support potential new labeling in areas such as “fatigue in narcolepsy” and “sleep inertia in IH,” and that the company has “utility patents out through 2044” for both GR and HD.

New pitolisant formulation targeting fatigue Dayno and Chief Medical and Scientific Officer Kumar Budur discussed an additional pitolisant formulation obtained via an exclusive license backed by an issued patent “until 2042.” Budur said Harmony’s interest in fatigue stems from its “multidimensional” nature—emotional, physical, and cognitive—and argued the histaminergic mechanism, including downstream norepinephrine and serotonin effects, is “uniquely positioned to address all three aspects of fatigue.”

Budur cited Harmony’s phase II proof-of-concept study in type 1 myotonic dystrophy, where about 90% of patients have significant fatigue, saying pitolisant improved fatigue “in a clinically meaningful way” and showed a “dose response.” He also noted pitolisant is labeled in Europe for residual excessive daytime sleepiness in obstructive sleep apnea. Based on characteristics of the newly licensed formulation, Budur said Harmony prioritized fatigue in multiple sclerosis because fatigue is “very well characterized” in MS and affects a large proportion of patients. He said the company is “optimizing the formulation” and expects the next step to be a phase I pharmacokinetic study.

Orexin program and EPX-100 in rare epilepsies Management also addressed the evolving orexin landscape and Harmony’s own orexin receptor agonist, BP1.15205. Zaeske said physicians show interest in orexins based on efficacy but still have questions about tolerability and longer-term data, citing reported adverse events such as “pretty high rates of insomnia,” frequent urination, and visual disturbances. He said Harmony expects a “gradual approach” to adoption and argued that new brands in narcolepsy historically expand branded utilization rather than solely shift share, reflecting a polypharmacy treatment paradigm. Zaeske said WAKIX’s “exceptional safety and tolerability” and “extremely clean profile” support its role as an add-on therapy.

Budur said BP1.15205 is “the most potent orexin receptor agonist in clinical development,” describing potency at “0.015 nanomolar levels,” a novel chemical scaffold intended to avoid off-target issues seen with earlier compounds, and a preclinical profile supportive of “potentially once-a-day dosing.” Dayno said Harmony expects top-line data from a phase I single-ascending-dose PK study in healthy volunteers “mid-year,” followed by an IND submission “mid-year” and a sleep-deprived healthy volunteer study to evaluate safety, tolerability, dose-ranging, and initial signals of efficacy.

In rare epilepsy, Budur discussed EPX-100, referencing open-label ARGUS data presented at AES showing a “50% median reduction” in CMS-28 from baseline. He emphasized EPX-100 is being developed as adjunctive therapy on top of multiple anti-epileptic drugs and said the program’s differentiation could include tolerability and safety, citing low rates of clinically relevant GI adverse events and no expected need for special routine monitoring such as LFT checks or echocardiograms required with other therapies. Dayno reiterated two phase III trials are advancing in Dravet syndrome and Lennox-Gastaut syndrome, with top-line data anticipated in 2027 and target PDUFA dates in 2028.

Dayno also highlighted business development as a key priority, citing “over $880 million on our balance sheet.” He said Harmony’s focus remains orphan and rare CNS and neuropsychiatric targets, but the company has “opened up the aperture” to consider broader indications adjacent to its sleep-wake and rare epilepsy franchises, including potentially “on market” assets and opportunities ranging from smaller tuck-ins to more transformational deals.

About Harmony Biosciences (NASDAQ:HRMY) Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

See Also Five stocks we like better than Harmony Biosciences

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommende.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences.

Goldman Sachs 47th Annual Global Healthcare Conference

Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit

Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527892644/en/

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD. The poster presentation details are as follows: Abstract Title Poster Presentation Session Treatment with Pitolisant in Subgroups of Adults with.